Sunday, 3 January 2016

Don't use the blog to Promote your own work

So how do you respond to this comment increase ProfGs altmetrics?;-)
  1. Optimizing treatment success in multiple sclerosis. Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S.J Neurol. 2015 Dec 24. [Epub ahead of print]
  2. IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension.Williams T, Marta M, Giovannoni G.Pract Neurol. 2015 Dec 11. pii: practneurol-2015-001275. doi: 10.1136/practneurol-2015-001275. [Epub ahead of print]
  3. Editors' Welcome.Banwell B, Giovannoni G, Hawkes C, Lublin F.Mult Scler Relat Disord. 2015 Nov;4(6):A1-2. doi: 10.1016/j.msard.2015.11.001.
  4. Systematic review and meta-analysis of salivary protein concentration in Parkinson's disease.Masters JM, Bestwick J, Warner TT, Giovannoni G, Proctor GB, Noyce AJ.Mov Disord. 2015 Nov 19. doi: 10.1002/mds.26462. [Epub ahead of print] 
  5. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Giovannoni G, Gold R, Fox RJ, Kappos L, Kita M, Yang M, Sarda SP, Zhang R, Viglietta V, Havrdova E.Clin Ther. 2015 Nov 1;37(11):2543-51. doi: 10.1016/j.clinthera.2015.09.011. Epub 2015 Oct 31.
  6. Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis. Bove R, White CC, Giovannoni G, Glanz B, Golubchikov V, Hujol J, Jennings C, Langdon D, Lee M, Legedza A, Paskavitz J, Prasad S, Richert J, Robbins A, Roberts S, Weiner H, Ramachandran R, Botfield M, De Jager PL.Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e162. doi: 10.1212/NXI.0000000000000162. eCollection 2015 Dec.
  7. Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.Phillips JT, Selmaj K, Gold R, Fox RJ, Havrdova E, Giovannoni G, Abourjaily H, Pace A, Novas M, Hotermans C, Viglietta V, Meltzer L.Int J MS Care. 2015 Sep-Oct;17(5):236-43. doi: 10.7224/1537-2073.2014-069.PMID: 26472945
  8. Atraumatic needles for lumbar puncture: why haven't neurologists changed? Davis A, Dobson R, Kaninia S, Giovannoni G, Schmierer K.Pract Neurol. 2015 Sep 8. pii: practneurol-2014-001055. doi: 10.1136/practneurol-2014-001055. [Epub ahead of print]
  9. Editors' Welcome.Banwell B, Giovannoni G, Hawkes C, Lublin F.Mult Scler Relat Disord. 2015 Sep;4(5):A1-2. doi: 10.1016/j.msard.2015.08.007.
  10. Multiple Sclerosis is a multifaceted disease.Banwell B, Giovannoni G, Hawkes C, Lublin F.Mult Scler Relat Disord. 2014 Sep;3(5):553-4. doi: 10.1016/j.msard.2014.07.005. Epub 2014 Aug 15.
  11. Elevated salivary protein in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity.Masters JM, Noyce AJ, Warner TT, Giovannoni G, Proctor GB.Parkinsonism Relat Disord. 2015 Oct;21(10):1251-5. doi: 10.1016/j.parkreldis.2015.07.021.
  12. Editors' Welcome.Banwell B, Giovannoni G, Hawkes C, Lublin. Mult Scler Relat Disord. 2015 Jul;4(4):A1-3. doi: 10.1016/j.msard.2015.07.001. 
  13. Is it time to target no evident disease activity (NEDA) in multiple sclerosis?Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M.Mult Scler Relat Disord. 2015 Jul;4(4):329-33. doi: 10.1016/j.msard.2015.04.006. Epub 2015 May 8.
  14. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, Giovannoni G, Miller D, Rashid W, Schmierer K, Shehu A, Silber E, Young C, Zajicek J. Pract Neurol. 2015 Aug;15(4):273-9. doi: 10.1136/practneurol-2015-001139.
  15. Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, von Rosenstiel P, Gottschalk R, Zhang Y, Dahlke F, Tomic D; TOFINGO study group.Neurology. 2015 Jul 7;85(1):29-39. doi: 10.1212/WNL.0000000000001706. Epub 2015 May 29. PMID: 26024899 
  16. Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). Absoud M, Gadian J, Hellier J, Brex PA, Ciccarelli O, Giovannoni G, Kelly J, McCrone P, Murphy C, Palace J, Pickles A, Pike M, Robertson N, Jacob A, Lim M.BMJ Open. 2015 May 25;5(5):e008312. doi: 10.1136/bmjopen-2015-008312. 
  17. Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. Rieckmann P, Boyko A, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Hommes O, Kesselring J, Kobelt G, Langdon D, LeLorier J, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P.Mult Scler Relat Disord. 2015 May;4(3):202-18. doi: 10.1016/j.msard.2015.02.005. Epub 2015. 
  18. Editors' welcome. Banwell B, Giovannoni G, Hawkes C, Lublin F. Mult Scler Relat Disord. 2015 May;4(3):181. doi: 10.1016/j.msard.2015.05.001. No abstract available. 
  19. Web-based assessment of Parkinson's prodromal markers identifies GBA variants.Noyce AJ, Mencacci NE, Schrag A, Bestwick JP, Giovannoni G, Lees AJ, Hardy J.Mov Disord. 2015 Jun;30(7):1002-3. doi: 10.1002/mds.26249. Epub 2015 May 13. 
  20. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P, Sidle K, Fish M, Orrell R, Howard R, Talbot K, Greensmith L, Kuhle J, Turner MR, Malaspina A.Neurology. 2015 Jun 2;84(22):2247-57. doi: 10.1212/WNL.0000000000001642. Epub 2015 May 1. Erratum 
  21. Multiple sclerosis outpatient future groups: improving the quality of participant interaction and ideation tools within service improvement activities.Thomson A, Rivas C, Giovannoni G. BMC Health Serv Res. 2015 Apr 23;15:105. doi: 10.1186/s12913-015-0773-8. 
  22. Timing is everything in the treatment of multiple sclerosis. McCarthy CL, Giovannoni G, Coles AJ.BMJ Case Rep. 2015 Apr 15;2015. pii: bcr2014208960. doi: 10.1136/bcr-2014-208960. PMID: 25878229 Paperpile
  23. Multiple sclerosis therapy and Epstein-Barr virus antibody titres. Raffel J, Dobson R, Gafson A, Mattoscio M, Muraro P, Giovannoni G. Mult Scler Relat Disord. 2014 May;3(3):372-4. doi: 10.1016/j.msard.2013.12.004. Epub 2013 Dec 31. PMID: 25876475. 
  24. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Kuhle J, Disanto G, Lorscheider J, Stites T, Chen Y, Dahlke F, Francis G, Shrinivasan A, Radue EW,Giovannoni G, Kappos L Neurology. 2015 Apr 21;84(16):1639-43. doi: 10.1212/WNL.0000000000001491. Epub 
  25. Editors' welcome. Banwell B, Giovannoni G, Hawkes C, Lublin F.  Mult Scler RelatDisord. 2015 Mar;4(2):93-4. doi: 10.1016/j.msard.2015.03.001. Epub 2015 Mar 18. No abstract available.
  26. Neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?Fine D, Dattani A, Moreira I, Giovannoni G, Marta M.Mult Scler Relat Disord. 2015 Jan;4(1):88-91. doi: 10.1016/j.msard.2014.11.007. Epub 2014 Nov 28.
  27. A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. Giovannoni G, de Jong B, Derfuss T, Izquierdo G, Mazibrada G, Molyneux P, Nicholas R, Overell J, Ziemssen T, Juliusson G.Mult Scler Relat Disord. 2015 Jan;4(1):83-4. doi: 10.1016/j.msard.2014.09.215. Epub 2014 Oct 13. 
  28. The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis? Giovannoni G, Baker D, Schmierer K. Mult Scler Relat Disord. 2015 Jan;4(1):3-5. doi: 10.1016/j.msard.2014.11.005. Epub 2014 Nov 21. 
  29. Editors׳ welcome. Banwell B, Giovannoni G, Hawkes C, Lublin F. Mult Scler Relat Disord. 2015 Jan;4(1):1-2. doi: 10.1016/j.msard.2014.12.002. Epub 2015 Jan 10. Select item 2576994636.
  30. The role of infections in Behçet disease and neuro-Behçet syndrome.Marta M, Santos E, Coutinho E, Silva AM, Correia J, Vasconcelos C, Giovannoni G.Autoimmun Rev. 2015 Jul;14(7):609-15. doi: 10.1016/j.autrev.2015.02.009. Epub 2015.
  31. Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse.Marques IB, Flanagan S, Noble H, Giovannoni G, Marta M. Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(2):e74. doi: 10.1212/NXI.0000000000000074. eCollection 2015 Apr. No abstract available. 
  32. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, Runia T, Evdoshenko E, Thouvenot E, Trojano M, Norgren N, Teunissen C, Kappos L, Giovannoni G, Kuhle J; on behalf of the International Clinically Isolated Syndrome Study Group.J Neurol Neurosurg Psychiatry. 2015 Feb 25. pii: jnnp-2014-309690. doi: 10.1136/jnnp-2014-309690. [Epub ahead of print]
  33. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre studyKuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV,Giovannoni G.Mult Scler. 2015 Jul;21(8):1013-24. doi:
  34. Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy.Biela A, Watkinson M, Meier UC, Baker D, Giovannoni G, Becer CR, Krause S.Biosens Bioelectron. 2015 Jun 15;68:660-7. doi: 10.1016/j.bios.2015.01.060. Epub 2015 Jan 28.
  35. CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.Elkins J, Sheridan J, Amaravadi L, Riester K, Selmaj K, Bielekova B, Parr E, Giovannoni G. Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(2):e65. doi: 0.1212/NXI.0000000000000065. eCollection 2015 Apr.
  36. Any evident MRI T2-lesion activity should guide change of therapy in multiple sclerosis--yes. Giovannoni G. Mult Scler. 2015 Feb;21(2):134-6. doi: 10.1177/1352458514566261. Epub 2015 Jan 26. No abstract available. 
  37. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Kappos L, Giovannoni G, Gold R, Phillips JT, Arnold DL, Hotermans C, Zhang A, Viglietta V, Fox RJ; DEFINE and CONFIRM study investigators.Eur J Neurol. 2015 Apr;22(4):664-71. doi: 10.1111/ene.12624. Epub 2015 Jan 2. 
  38. Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D.J Neuroimmune Pharmacol. 2015 Jun;10(2):281-92. doi: 10.1007/s11481-014-9575-8. Epub 2014 Dec 24. 
  39. Developing Biomarkers for MS. Gnanapavan S, Giovannoni G. Curr Top Behav Neurosci. 2015;26:179-94. doi:
  40. HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study.Gold J, Goldacre R, Maruszak H, Giovannoni G, Yeates D, Goldacre M. J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):9-12. doi: 10.1136/jnnp-2014-307932. Epub 2014 Aug 4. 
  41. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. Lu CH, Petzold A, Topping J, Allen K, Macdonald-Wallis C, Clarke J, Pearce N, Kuhle J, Giovannoni G, Fratta P, Sidle K, Fish M, Orrell R, Howard R, Greensmith L, Malaspina A. J Neurol Neurosurg Psychiatry. 2015 May;86(5):565-73. doi: 10.1136/jnnp-2014-307672. Epub 2014 Jul 9. 
  42. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Meltzer L, Kurukulasuriya NC.Mult Scler. 2015 Jan;21(1):57-66. doi: 10.1177/1352458514537013. Epub 2014 Jul 2. 
  43. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome.Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A, Lu CH, Dobson R, Disanto G, Norgren N, Nissim A, Kappos L, Hurlbert J, Yong VW, Giovannoni G, Casha S.
CoI: multiple

2 comments:

  1. No wonder Prof G looks tired and worn out!

    ReplyDelete
  2. Beckons some questions:

    A. What is wrong with using ones own blog to promote one's own work not that I see that as the case here. If no entity working towards public welfare should promote their own work that would mean every not for profit operation on the planet is across the ethical equator.

    B. Some of us (especially my other half Cynthia) finds folks such as Prof G. inspirational even when her posts may end up on the cutting floor. She has told me on more than one occasion that his dedication helps keep her going on our work. She retweets rather religiously and wonders why others do not. She does this with the societies stuff too as she catches it. Asks why others do not. I told her, its about marketing per se. Then I become "victim". "Well is not this about people with MS? Like me? Like millions of others? Is'nt it about helping people, understanding this disease, getting rid of it?".... "Ummm.... yes Dear".

    You all keep doing exactly what you are doing and do not worry about malcontents.

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.